IL-12 can enhance the development of effective immune express the two subunits from the same vector, the p35 responses against tumors as well as against certain infecand the p40 cDNAs were cloned into pSFV1, each under tious agents. It is therefore a potential candidate for therathe control of a subgenomic SFV promoter. Recombinant peutic use in cancer therapy and in the design of vaccines RNA produced by in vitro transcription of SFV-IL-12 conagainst several infectious diseases. Several studies have struct, was packaged into SFV viral particles with the use demonstrated that IL-12 could efficiently induce tumor of a non-packageable helper RNA. We show that human regression in animal models. To investigate the antitumor tumor cell lines infected in vitro and in vivo with recombieffect of direct gene transfer of human IL-12 into tumors, nant SFV-IL-12 viral particles secrete high levels of biologihuman IL-12 p35 and p40 cDNAs were cloned into the cally active heterodimeric p35/p40 IL-12, as demonstrated Semliki Forest virus (SFV) vector pSFV1. In order to using ELISA and biological assays.
Introduction
growth of both established subcutaneous tumors and Numerous studies in animal models have indicated that hepatic metastases in mice. 12 Furthermore, local injections the expression of various cytokine genes in tumor cells of IL-12 at the periphery of the tumor have led to generally results in a dramatic alteration of tumor cell regression of established subcutaneous tumors. 12 growth and in induction of tumor-specific immunity. 1 Recently, the anti-angiogenic effect of IL-12 has also been These studies clearly established that tumor vaccines reported. 13 All these properties of IL-12 make it partibased on the use of cytokines could be a valuable way cularly valuable in gene therapy. Interestingly, the effects of eliciting a specific antitumor response against poorly of paracrine secretion of IL-12 on tumor establishment in immunogenic tumors.
vaccination models indicate that local delivery of IL-12 Interleukin-12, a heterodimeric cytokine consisting of can induce an immune response against poorly immunotwo disulfide-bonded subunits of 35 kDa and 40 kDa, [2] [3] [4] genic tumors. 14 is secreted by antigen presenting cells (APC). 5 IL-12 has The development of methods in gene transfer suitable a critical early role in the induction of T cell-mediated for tumor therapy is a major focus of research at the immunity. It binds to its receptor on T cells and natural present time. In most studies performed to date, retrokiller (NK) cells, 6, 7 and it promotes the induction of primvirus, adenovirus and adeno-associated virus vectors arily T helper 1 (Th1) response in vitro and in vivo, 8, 9 leadhave been used to deliver cytokine genes in mammalian ing to cellular-mediated immunity. IL-12 appears to be a cells. 15 Vaccinations performed in the different protocols physiologic inducer of IFN␥ production by T and NK induced efficient antitumor immunity, which significells. 10 Injecting recombinant murine IL-12 into mice cantly reduced the malignancy of parental cells inocuincreases NK activity, enhances allogeneic cytolytic T cell lated subsequently. [16] [17] [18] Recently, a new vector system responses and induces secretion of IFN␥. 11 Systemic based on Semliki Forest virus (SFV) was reported. 19 The SFV system is suicidal and characterized by high expression levels and broad host range. 20 This system has already been shown to be effective in recombinant vaccine studies, [21] [22] [23] suggesting that it could be successfully used for in vivo expression of cytokines. The current study was undertaken to analyze the possibility of using an SFV vector as a new method of expressing human IL-12 in
Results
subunit was indeed synthesized when the corresponding message was included in the recombinant SFV RNA. The Cloning of human IL-12 p35 and p40 cDNAs into two subunits were produced, heterodimerized and were pSFV1 secreted in the culture medium when the respective The two IL-12 subunit genes were first individually mRNAs were cotransfected (data not shown). cloned under the subgenomic promoter of pSFV1
Subsequently, a double construct was made to enable ( Figure 1) . Restriction enzyme map analysis and sequensimultaneous expression of both genes in the same cell. cing were performed in order to verify the correct orienFor this purpose, a 1.1 kb fragment was isolated from the tation and the integrity of the cloned fragments.
pSFV1-p35. This fragment contained the 26S promoter, Expression of p35 and p40 subunits of IL-12 was moniupstream of the p35 cDNA and was cloned into the pSFV1-p40 downstream of the p40 cDNA, at the SmaI site ( Figure 1 ).
Expression of human IL-12 in BHK21 cells
To package SFV-IL-12 RNA into SFV capsid and envelope, BHK21 cells were cotransfected with both SFV-IL-12 RNA and SFV-helper2 RNA (Figure 2 ). Virus titration was performed as described in Materials and methods. BHK-21 cells, subsequently infected with the activated recombinant viral particles, produced hIL-12, as measured by ELISA. Western blotting was performed for further characterization of IL-12. The SFV product was compared to a control hIL-12 produced in a baculovirus system. Under nonreducing conditions, one band was revealed with an estimated MW of 85 kDa, which is slightly heavier than the control hIL-12 ( Figure 3a) . Under reducing conditions, two bands were revealed corresponding to the p35 and p40 subunits, but were heavier than control recombinant p35 and p40 ( Figure 3b ). This discrepancy in molecular weight is assumed to be due to a variation in the glycosylation pattern of the IL-12 protein produced in mammalian cells compared to IL-12 derived from insect cells. These Western blotting experiments indicated that both p40 and p35 subunits were produced at comparable levels.
IL-12 produced by SFV-IL-12 induced production of IFN␥ by PBMC The biological activity of IL-12 produced by SFV-IL-12-infected BHK-21 cells was measured in an IFN␥ induction assay, as previously described. 10 The assay is based on the synergistic effect of IL-12 and PHA on the induction of IFN␥ production by PBMC. Results presented in Figure 4 confirmed that hIL-12 produced in BHK21 cells infected by SFV-IL-12 is biologically active. The enhancement of IFN␥ production by IL-12 produced by the SFV system was IL-12-specific. Adding a neutralizing anti-IL-12 antibody resulted in complete inhibition of IL-12-induced IFN␥ production by PBMC.
Infection of human tumor cells in vitro and in vivo and kinetics of IL-12 expression Human tumor cell lines of breast, ovary, neuroblast, lung and kidney origins were infected to assess how efficiently Human A549 tumor-bearing nude mice were injected
Figure 2 Production of recombinant SFV-IL-12 particles. pSFV-IL-12 was linearized by SpeI treatment and in vitro transcribed into RNA by SP6 RNA polymerase. pSFV-Helper 2 carrying the SFV envelope and capsid genes was similarly linearized and transcribed into RNA. A mixture of these RNA populations was transfected into BHK-21 cells, where IL-12 mRNA and SFV structural protein mRNAs were replicated by SFV replicase and translated into free IL-12 and newly formed noninfectious recombinant SFV particles containing pSFV-IL-12 RNA. Chymotrypsin cleavage of the envelope of recombinant SFV particles yielded infectious particles able to initiate a new round of infection.
intratumorally with SFV-IL-12 to assess in vivo IL-12 pro-SFV-IL-12 or SFV-LacZ as a negative control. Infection by SFV-IL-12 induced production of biologically active duction induced by this virus. Sera of mice injected with 10 7 IU SFV-IL-12 contained around 10 ng/ml IL-12 at human IL-12 which in turn induced proliferation of activated PBMC, whereas control supernatants from cells 24 h, 4 ng/ml at 48 h and 1.5 ng/ml at 72 h after infection, as determined by an IL-12 ELISA. The production of hILinfected with SFV-LacZ did not ( Figure 6 ). 12 in mice sera was dose-dependent (4 ng/ml IL-12 for 10 7 IU; 0.05 ng/ml IL-12 for 10 5 IU). confirming that a tumor-specific memory response had been induced.
It is now clearly established that IL-12 is a key regulatory cytokine in the immune system with potent antitumor functions. IL-12 plays a pivotal role in the regulation of cell-mediated cytotoxicity and in the modulation of the cytokine network. 9 In murine studies, IL-12 has been shown to prevent growth of a wide spectrum of tumors in vivo. Treatment of poorly immunogenic tumors efficiently in enhancing proliferation and differentiation of effector cells, so that they eradicate tumor cells more efficiently. 26 Furthermore, fibroblasts genetically engineered to secrete murine IL-12 have already been reported efficient at inducing hIL-12 expression in tumor-bearing mice injected intratumorally with SFV-IL-12. to elicit profound antitumor effects in murine models. 14 
Several types of vehicles can be used to transfer genes
Inoculation of tumor cells genetically engineered to secrete cytokines is followed by the development of antiinto tumor cells for the purpose of gene therapy, including disabled viruses such as retroviruses, adenoviruses, gen-specific immunity. Studies in a variety of models suggested that in addition to transgenes, the first generadeno-associated viruses and herpes viruses, [16] [17] [18] ,24,27 but also nonviral approaches such as the injection of naked ation adenoviral vectors expressed viral proteins which activated CTL leading to destruction of virus-infected DNA, liposomes containing cDNA or DNA-coated particles. 15 With the new expression system, based on the cells. Another limitation of gene therapy with recombinant adenoviruses was that cytokine gene expression SFV replicon, expression is highly efficient and limited to one cell cycle without concomitant expression of any could not be detected readily after a second administration of the virus. Resistance to repeated gene therapy viral structural genes. 19 Human tumor cell lines infected with SFV-IL-12 recomhas been recently reported to be associated with the development of antiviral neutralizing antibodies. 29 Interbinant virus could express similar levels of both IL-12 subunits (p35 and p40), 28 as evidenced by Western blot. estingly, the SFV vector is less immunogenic since no structural proteins are produced in the host cells. 23 The Our findings also indicated that IL-12 produced by transfected tumor cells could efficiently induce IFN␥ prouse of the SFV expression system for gene transfer therapy may also avoid possible oncogene activation by inteduction by PBMC (Figure 5 ), stimulating PHA-activated PBMC growth ( Figure 6 ) and inducing the generation of gration of the retroviral vector. Another advantage of using the SFV expression system LAK cells (Figure 7) . In vivo, this recombinant virus was for gene transfer in tumor therapy is that cells infected SmaI sites. Both the p35 DNA and pSFV1 were then cut by XmaI and ligated by T4 DNA ligase after dephoswith SFV are committed to die after infection and cytokine secretion. It is then tempting to speculate that, in phorylation of pSFV1. By PCR amplification, we introduced a BamHI site at the 5Ј end and a SmaI site at the vivo, dead cells would provide the tumor-infiltrating lymphocytes with tumor antigens released at the tumor site, 3Ј end of the p40 gene using 5Ј-gATCggATCCCACTATTATAgCACCATgTgTgTCACCAgCAgTTggTC-3Ј and together with high levels of cytokine. Local cytokine and tumor antigen production would therefore increase CTL 5Ј-ATCCCCgggCTAACTgCAgggCACAgA-3Ј as primers, respectively. The product of amplification was subexpansion, the recruitment of helper T cells and NK cells and the enhancement of the host APC function, while sequently cloned into pSFV1 at BamHI and SmaI sites. In order to clone the two subunits into the same plasmid, minimizing systemic toxicity. The SFV vector may prove to be a valuable means of enhancing a protective local the pSFV1-p35 was partially digested with SmaI and completely cut at the HindII site. After purification from 1% and systemic immune response against a small tumor burden. Moreover, one would expect the released tumor agarose gel, the 1.1 kb fragment was ligated into the pSFV1-p40 at the SmaI site. The pSFV1-IL-12 plasmid was antigens to activate local immune or inflammatory responses, leading to protection from even poorly then electroporated into SURE bacteria (Stratagene, Heidelberg, Germany), to verify the right insertion orientation. immunogenic tumors. However, since IL-12 expression using SFV-IL-12 can be obtained only for short periods
Packaging of SFV-IL-12 RNA in viral particles (3 days), it will be important to assess the consequences The pSFV1-IL-12 DNA was linearized at the SpeI site. USA) and subjected to electroporation at 800 V, 25 F, fetal calf serum, 10% tryptose phosphate broth, 10 mm with two consecutive pulses. Cells were then diluted HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic with complete medium in a tissue culture plate and incuacid) and 2 mm l-glutamine at 37°C, 5% CO 2 . Tumor cells bated for 24 h. While SFV-IL-12 RNA is packaged into used in this study were grown either in RPMI 1640 SFV virions, the helper RNA is not, due to the lack of the medium (ovarian tumor cell line OV-1 IGR, neuroblaspackaging sequence. Moreover, produced particles are toma MAT 36, breast tumor cell line MCF7, lung tumor noninfectious due to a mutation in the envelope gene, cell line A549) or in DMEM medium (kidney tumor cell which necessitates in vitro chymotrypsin treatment in lines UOK and ENT), 100 U/ml penicillin, 100 g/ml order to be infectious. Such a design strategy avoids the streptomycin, 2 mm l-glutamine, supplemented with 5% appearance of recombinant wild-type infectious particles fetal calf serum, at 37°C, 5% CO 2 . The infection medium and limits virus propagation to a single cycle.
30
was BHK, RPMI 1640 or DMEM medium containing 0.2% The BHK-21 cell culture supernatant was then spun at bovine serum albumin (BSA), 10 mm HEPES, and 2 mm 400 g for 20 min and viral particles were harvested from l-glutamine. the supernatant by ultracentrifugation at 100 000 g, for Blood from healthy donors was obtained by leuko-1.5 h at 4°C. The pellet of viral particles was resuspended phoresis (Banque du Sang, Hô pital Saint Louis, Paris, in a suitable volume of TNE buffer (50 mm Tris-HCl France). Peripheral blood mononuclear cells (PBMC) pH 7.4, 100 mm NaCl, 0.5 mm EDTA), in order to achieve were isolated using Ficoll-Hypaque (Pharmacia, a 100-fold concentration. Uppsala, Sweden) and cultured in RPMI 1640 medium, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mm lInfection of cells by the viral particles glutamine, supplemented with 15% fetal calf serum, at Activation of the SFV-IL-12 virus was performed with 37°C, 5% CO 2 . 0.5 mg/ml of chymotrypsin (Sigma) and 10 mm CaCl 2 PHA was obtained from Sigma Chemicals (St Louis, (Sigma), at room temperature for 30 min and stopped by MO, USA). H-thymidine was purchased from Ameradding aprotinin at a final concentration of 0.6 mg/ml sham (Little Chalfont, Bucks, UK).
(Sigma). Human tumor cells or BHK-21 cells were left to adhere overnight, washed twice with PBS and then Cloning of IL-12 p35 and p40 subunits in the SFV covered with the activated virus at an MOI of 10, diluted vector in infection medium. Infection was performed at room The pSFV1, pSFV-helper2 and pSFV3-LacZ vectors have temperature for 30 min, prolonged by 15 min at 37°C, been described previously. 19, 23, 30 We introduced a SmaI with gentle tilting from time to time. The virus solution site at the two ends of hIL-12 p35 cDNA by PCR amplifiwas then removed and replaced by the complete medium cation, using the following primers: 5Ј-gATCCCCgggATfor further incubation. TATAgCACCATgTgTCCAgCgCgCAgCCTCC-3Ј and 5Ј-gATCCCCgggTTAggAAgCATTCAgATAgC-3Ј, that conVirus titration Two hours after infection, monensin (Sigma) was added tain p35 homologous regions for hybridization with p35 cDNA and nonhomologous regions which introduce to the culture medium to a final concentration of 9 m, in order to suppress IL-12 secretion. After another 3-10 h of 4 × 10 4 PHA-activated PBMC were seeded in 96-microwell plates and stimulated with diluted superincubation, cells were washed twice with PBS and fixed with PBS containing 3% formaldehyde for 30 min at 4°C.
natants from cells infected with SFV-IL-12 or SFV-LacZ.
Cultures were incubated at 37°C in 5% CO 2 for 48 h. 3 HCells were then washed twice with PBS containing 0.3% Triton-X100 (Sigma). Nonspecific binding of antibody thymidine incorporation was determined during the last 6 h of culture (1 Ci per well). IL-12 was kindly provided was prevented by incubation in PBS containing 0.3% Triton-X100 and 0.5% BSA (Sigma) for 30 min at room temby Genetic Institute (Boston, MA, USA). perature. The first murine antihuman IL-12 monoclonal antibody (R&D Systems, Oxford, UK) was incubated at LAK activation: Purified PBMC (10 6 /ml) were cultured the appropriate dilution for 30 min at room temperature.
for 6 days in the presence of supernatants from cells After three washings in the same medium, the second infected with SFV-IL-12 or SFV-LacZ, or in the presence sheep antimouse monoclonal antibody conjugated with of sera of tumor-bearing mice injected with SFV-IL-12 or FITC (Amersham) was incubated at the appropriate SFV-LacZ. Cells were then harvested, washed three times dilution for 30 min at room temperature. Cells were and used as effector cells in a 51
Cr-release cytolysis assay finally washed three times with PBS and once with disas previously described. 31 The B lymphoblastoid cell line, tilled water. Fluorescent cells were then examined for Daudi, resistant to NK cell lysis, was used as target. Pertitration under a UV microscope. One fluorescent cell was centage of specific lysis was calculated as follow: considered to be infected by one infection unit (IU).
100 × (experimental release) − (spontaneous release) (maximal release) − (spontaneous release) Infection of tumor-bearing mice by SFV-IL-12 Swiss nude mice were bred at the animal facility of the Values are the mean of triplicate wells, with a standard Institut Gustave-Roussy, Villejuif, France. Subcutaneous deviation of usually Ͻ10%. Association pour la Recherche sur le Cancer (C6227), the After the specified time period, retro-orbital bleed was Ligue contre le Cancer, the Institut Gustave-Roussy and performed and serum was collected after centrifugation.
the FEGEFLUC. bution. We would also like to thank A Abina for in vivo Systems) were subjected to 10% SDS-PAGE in nonreducexperiments, and L St-Ange for kindly correcting the ing conditions or 12% SDS-PAGE in reducing conditions, manuscript. and blotted on to a Protran BA 85 cellulose nitrate membrane (Schleicher & Schuell, Diassel, Germany). IL-12 was revealed using anti-p35 (Pharmingen, San Diego, CA,
